Letter From The Editor

Over the past two months we have provided you with a special GLP-1 newsletter. During this time we have seen that the science behind this class of drugs known as GLP-1- Analogs is solid and the results are positive. Many of you asked for more information on how the native …

If you do enough interviews you are bound to get a few great ones. Often when we talk to researchers they either hold back on information that they are afraid to share or they try to be experts on everything we ask them. Our publisher, Steve Freed, had a chance …

Misconceptions abound when it come to diabetes, and this week’s Clinical Mastery Newsletter looks at a couple of them. Our Clinical Case Study looks at the reasons why telling patients that they are “borderline” may not be a good idea and our Diabetes Disaster Averted points out the problems that …

Each time I sit down with a group of patients to talk about food choices for diabetes the topic of carbohydrates always comes up. I get a lot of groans when I talk about counting carbs and keeping track, but for the past few months I have been focusing on …

There’s been some interesting research on a compound that appears to be a partner peptide for GLP-1. Oxyntomodulin is released in response to a meal and seems to have a significant effect on glucose levels. Our current PharmD candidate, Farhan Guard, from Lake Erie College of Medicine, found out about this …

There has been a shortage of methylprednisolone and prednisone dose packs available in pharmacies lately and this week’s Disaster Averted deals with what happens when patients get their anti-inflammatory steroids in a bottle instead of a pack. If you’re thinking that the problem is hyperglycemia then you need to review …

The National Committee for Quality Assurance (NCQA) recently held a series of webinars to help clinicians in “Achieving and Outperforming Type 2 Diabetes HEDIS Measures.“ There were a lot of elements that needed to fall into place to make that happen and our Pharm D candidate, Daniel Schultz, listened in …

This week we get back to our interview with Dr. Aaron Vinik, Director, EVMS Strelitz Diabetes Research Center. He has been at the forefront in developing new technologies for growing and regenerating beta cells. Our publisher, Steve Freed, had a few questions for him on how he views the use …

Many times our patients get a Glucagon Kit when they start on insulin and since most patients are taught to only use the injection if they are unconscious, they never use it. However, in this week’s Diabetes Disaster Averted, the use of part of a glucagon injection kit was very …

There was a news release that caught my attention this past week. Eli Lilly announced that the Exenatide tQT Study Showed No Prolongation of QT Interval (See this week’s Item #1). Back in March most of us thought that the FDA would approve the once weekly dose, but instead they …